GeoVax Pledges Continued Support for Vaccine Innovation, Transparency, and Public Health
ATLANTA, GA - February 18, 2025 ( NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a leader in vaccine and immunotherapy development, congratulates Robert F. Kennedy, Jr. on his confirmation as Secretary of the U.S. Department of Health and Human Services (HHS). RFK Jr.'s appointment provides a significant opportunity for healthcare innovation, transparency, and public trust, reinforcing national priorities such as vaccine safety, diversified vaccine platforms, and strengthened domestic manufacturing. GeoVax stands ready to support these initiatives by delivering next-generation vaccines and advanced vaccine manufacturing technology that enhance biosecurity, public health resilience, and vaccine confidence.
GeoVax's Commitment to a Robust, Transparent and Secure Vaccine Future
GeoVax's mission aligns closely with the new administration's policy priorities, particularly in reducing reliance on foreign pharmaceutical supply chains, increasing vaccine safety and durability, and ensuring access for underserved populations. The Company's proprietary Modified Vaccinia Ankara (MVA) platform offers a promising alternative to other vaccine technologies such as mRNA, providing broad-spectrum, durable immunity across multiple infectious diseases via a recognized safe vaccine platform.
Key initiatives supporting the goals for vaccine safety and transparency include:
Diversified Vaccine Development – GeoVax's GEO-CM04S1, a next-generation COVID-19 vaccine, and GEO-MVA, a dual-purpose Mpox and smallpox vaccine, align with the advocacy for alternative vaccine platforms beyond mRNA. These vaccines are designed to offer long-term immunity with a well-documented safety profile.
Transparency as a Pillar of Public Trust – As David Dodd, Chairman and CEO of GeoVax, has emphasized, restoring trust in vaccines requires clear communication, open regulatory processes, and full transparency regarding safety, efficacy, and potential risks. GeoVax supports the call for greater industry accountability and public engagement, ensuring that vaccine development aligns with the highest standards of ethical science.
Strengthening U.S. Biosecurity – GeoVax's anticipated domestic vaccine manufacturing capabilities reinforce the bipartisan legislative commitment to reducing dependence on foreign pharmaceutical supply chains, thereby enhancing national pandemic preparedness.
Ethical Vaccine Development & Public Confidence – GeoVax embraces open regulatory processes, rigorous safety standards, and public access to data, ensuring confidence in its vaccines. These principles align with the call for increased scrutiny and transparency in vaccine development and approval.
Equitable Access & Global Preparedness – With cost-effective, scalable technology that does not require ultra-cold storage, GeoVax's vaccines are well-suited for domestic and global distribution, ensuring broad access to critical immunizations, particularly for immunocompromised and underserved communities.
David Dodd: 'Transparency is the Key to Restoring Vaccine Trust'
Reflecting on the challenges of vaccine hesitancy, David Dodd has been a vocal advocate for transparency in vaccine development and regulatory processes. In a recent op-ed, he emphasized: 'Trust in vaccines has become a critical battleground for public health. Addressing public concerns openly and honestly is the only way to bridge the growing divide between science and skepticism. Transparency is a necessity, not an option. GeoVax remains committed to clear communication, scientific integrity, and ensuring that public confidence in vaccines is based on facts, not fear.' ( https://www.genengnews.com/topics/translational-medicine/a-call-to-action-building-vaccine-trust-through-transparency/)
This perspective directly supports the stated goals of strengthening public trust, reducing regulatory opacity, and ensuring vaccine safety through independent oversight. GeoVax's proactive approach to transparent vaccine development is a model for responsible biotech leadership.
A New Era for U.S. Healthcare and Pandemic Preparedness
RFK Jr.'s confirmation as HHS Secretary provides a renewed opportunity in support of vaccine diversification, transparency, and strategic biomanufacturing initiatives. GeoVax's innovative vaccine pipeline supports these goals, positioning the Company as a vital partner in safeguarding national and global public health.
GeoVax's vaccine development strategy builds upon successful national initiatives, such as Operation Warp Speed and Project NextGen, by prioritizing pandemic preparedness and biosecurity resilience. Through continued engagement with federal agencies and global health organizations, the Company seeks to accelerate vaccine development, expand domestic manufacturing, and enhance pandemic response efforts.
David Dodd, Chairman and CEO of GeoVax, stated: 'Secretary Kennedy's confirmation presents an opportunity to redefine public health with greater emphasis on safety, accessibility, and innovation. GeoVax proudly supports the commitment to reducing dependence on foreign pharmaceutical supply chains, diversifying vaccine technology, and restoring trust in public health solutions. We stand ready to collaborate with HHS and other healthcare stakeholders to advance a safer, more resilient healthcare future.'
About GeoVax
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines for many of the world's most threatening infectious diseases and therapies for solid tumor cancers. The company's lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine for which GeoVax was recently awarded a BARDA-funded contract to sponsor a 10,000-participant Phase 2b clinical trial to evaluate the efficacy of GEO-CM04S1 versus an approved COVID-19 vaccine. In addition, GEO-CM04S1 is currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin(R), having recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. A Phase 2 clinical trial in first recurrent head and neck cancer, evaluating Gedeptin(R) combined with an immune checkpoint inhibitor is planned. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products. The Company has a leadership team who have driven significant value creation across multiple life science companies over the past several decades. For more information about the current status of our clinical trials and other updates, visit our website: www.geovax.com.
Forward-Looking Statements
This release contains forward-looking statements regarding GeoVax's business plans. The words 'believe,' 'look forward to,' 'may,' 'estimate,' 'continue,' 'anticipate,' 'intend,' 'should,' 'plan,' 'could,' 'target,' 'potential,' 'is likely,' 'will,' 'expect' and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax is able to obtain acceptable results from ongoing or future clinical trials of its investigational products, GeoVax's immuno-oncology products and preventative vaccines can provoke the desired responses, and those products or vaccines can be used effectively, GeoVax's viral vector technology adequately amplifies immune responses to cancer antigens, GeoVax can develop and manufacture its immuno-oncology products and preventative vaccines with the desired characteristics in a timely manner, GeoVax's immuno-oncology products and preventative vaccines will be safe for human use, GeoVax's vaccines will effectively prevent targeted infections in humans, GeoVax's immuno-oncology products and preventative vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete development, there is development of competitive products that may be more effective or easier to use than GeoVax's products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control.
Further information on our risk factors is contained in our periodic reports on Form 10-Q and Form 10-K that we have filed and will file with the SEC. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.
678-384-7220
212-698-8696
Media Contact:
202-779-0929
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
GDS Announces Official Listing and Trading of its C-REIT on the Shanghai Stock Exchange from 8 August, 2025
SHANGHAI, China, Aug. 05, 2025 (GLOBE NEWSWIRE) -- GDS Holdings Limited ('GDS Holdings', 'GDS' or the 'Company') (NASDAQ: GDS; HKEX: 9698), a leading developer and operator of high-performance data centers in China, today announced that its previously announced China REIT ('C-REIT') will be officially listed and start trading on the Shanghai Stock Exchange from 8 August, 2025, under the fund code 508060. About GDS Holdings Limited GDS Holdings Limited (NASDAQ: GDS; HKEX: 9698) is a leading developer and operator of high-performance data centers in China. The Company's facilities are strategically located in and around primary economic hubs where demand for high-performance data center services is concentrated. The Company's data centers have large net floor area, high power capacity, density and efficiency, and multiple redundancies across all critical systems. GDS is carrier and cloud-neutral, which enables its customers to access the major telecommunications networks, as well as the largest PRC and global public clouds, which are hosted in many of its facilities. The Company offers co-location and a suite of value-added services, including managed hybrid cloud services through direct private connection to leading public clouds, managed network services, and, where required, the resale of public cloud services. The Company has a 24-year track record of service delivery, successfully fulfilling the requirements of some of the largest and most demanding customers for outsourced data center services in China. The Company's customer base consists predominantly of hyperscale cloud service providers, large internet companies, financial institutions, telecommunications carriers, IT service providers, and large domestic private sector and multinational corporations. The Company also holds a non-controlling 35.6% equity interest in DayOne Data Centers Limited which develops and operates data centers in International markets. For investor and media inquiries, please contact: GDS Holdings LimitedLaura ChenPhone: +86 (21) 2029-2203Email: ir@ Piacente Financial CommunicationsRoss WarnerPhone: +86 (10) 6508-0677Email: GDS@ Brandi PiacentePhone: +1 (212) 481-2050Email: GDS@ GDS Holdings Limited
Politico
28 minutes ago
- Politico
After BLS firing, Trump leaves clean-up job to successor
Fed Chairman Jerome Powell also frequently praises the quality of U.S. economic data, but in a June appearance before the House Financial Services Committee, he warned of 'very mild degradation of the scope of the surveys.' 'The direction of travel is something I'm concerned about,' he said. 'I don't like to see the kind of stories I'm reading, the idea being that the data is going to become more volatile and less reliable.' The quality of that data has shown growing signs of strain since Trump returned to the White House. Trump's federal hiring freeze has made it harder for the bureau to restaff its data collection and processing teams, even though key BLS positions were excluded from DOL's buyout offer. The bureau has eliminated hundreds of indices that measure wholesale prices, and BLS stopped collecting data in smaller markets like Provo, Utah, and Buffalo, N.Y. In the rest of the country, the number of price inputs used to calculate the consumer price index — one of the primary gauges for inflation — has declined by about 15 percent. 'I don't know how you address that because you're not allowing them to hire people to replace the attrition,' said Omair Sharif, president of the firm Inflation Insights. 'This person coming in has got a huge, huge challenge because they're starting off behind the eight-ball from a credibility perspective.' The White House has terminated voluntary boards that had advised the agency on statistical methodology and how economic changes could affect data-collection efforts and analysis. And Trump's budget proposes transferring BLS over to the Commerce Department, bundling it with two other statistical agencies. That worrisome trend has dovetailed with a yearslong drop in response rates that accelerated after the pandemic — putting into question the effectiveness of such a foundational methodology for BLS. Potential solutions — including shifts that would allow participants to self-administer a key survey used to measure unemployment — are underway. But Trump's heavy-handed reaction to a negative jobs report risks undercutting that progress, said Susan Houseman, a senior economist at the Upjohn Institute for Employment Research who had previously chaired the agency's Technical Advisory Committee. 'Criticizing — with no basis — the BLS and other statistical agencies for fabricating numbers can have very bad effects on response rates,' she said. 'This kind of talk really can damage that and further undermine data quality.' To be sure, resource constraints predate Trump. One White House official granted anonymity to speak frankly about the administration's thinking said that the BLS has had 'clear problems with the reliability and accuracy of its employment statistics since the start of Covid.' A Labor Department official granted anonymity to describe what contributed to McEntarfer's ouster told POLITICO that agency leadership was repeatedly kept in the dark about cutbacks BLS made due to financial constraints and did not respond to offers to find solutions.
Bloomberg
28 minutes ago
- Bloomberg
Modi, Marcos Pledge Closer Defense Ties Amid Rising China Threat
Indian Prime Minister Narendra Modi and Philippine President Ferdinand Marcos Jr. met in New Delhi on Tuesday and agreed to deepen their military partnership, at a time when China is becoming increasingly assertive in the Indian Ocean. 'We have agreed to continue leveling up our collaboration in defense and security,' Marcos said at a briefing in New Delhi, adding that the 'expanding capabilities and footprint' of India's domestic defense manufacturing industry would support the Philippines' ongoing military modernization.
